Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care, urology and surgery, will
showcase the product portfolio recently acquired from its new
subsidiary, Vascular Solutions, as well as its Arrow® Hemodialysis,
Oncology and Peripheral Intervention Solutions at the CIRSE
Congress being held in Copenhagen, Denmark, on September 16-20,
2017.
With the recent acquisition of Vascular Solutions, Teleflex now
offers clinical solutions for minimally invasive coronary and
peripheral vascular interventions, with a full line of products
that give vascular specialists the tools they need to handle
routine and complex cases. Clinicians worldwide rely on the quality
and proven clinical utility of products from Vascular Solutions,
such as the Turnpike® Catheter, Pronto® Extraction Catheter, Micro
Elite™ Snare, Expro Elite™ Snare and Hunter™ Biopsy Sealing
Device.
The Arrow® OnControl® Powered Bone Access System offers the
ability to effectively, safely and rapidly obtain high quality bone
samples.1,2,3,4 Our bone lesion biopsy needle is designed
specifically for multiple bone biopsies from a single cortical
penetration. Using our patented handheld driver technology, the
Arrow® OnControl® Powered Bone Access System provides
interventional radiologists a fast, reliable solution for accessing
dense and hard-to-reach bone lesions.5
The ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter has
an innovative tip designed to produce a helical, three-dimensional
transition of blood entering and leaving the catheter.6 Designed
for optimum performance, this tunneled hemodialysis catheter, with
symmetrical tip designed to reduce loss of lock solution7 (a
contributing factor in reducing the risk of thrombus adherence8),
gives sustained high flows, minimizes recirculation and reduces the
risk of platelet damage resulting from shear stress.9
During the CIRSE Congress on Saturday, September 16, Teleflex is
running two “Central Lines and Ports” Hands-on Device Training
Sessions (CLP-HDT), featuring Timothy W.I. Clark MD (Director of
Interventional Radiology at Penn Presbyterian Medical Center,
Associate Professor of Clinical Radiology) and Alain Storms
(Product Manager, Teleflex) as presenters. CLP-HDT 1 will take
place from 09:30-11:00 and CLP-HDT 2 will take place from
12:30-14:00, both in HDT Room 1.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, ARROW-Clark, Expro Elite,
Deknatel, Hudson RCI, Hunter, LMA, Micro Elite, OnControl, Pilling,
Pronto, Rüsch, Turnpike, VectorFlow, and Weck are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries.© 2017 Teleflex Incorporated.
All rights reserved.
References:
1. Berenson JR, Yellin O, Blumenstein B, et al. Using a powered
bone marrow biopsy system results in shorter procedures, causes
less residual pain to adult patients, and yields larger specimens.
Diagnostic Pathology 2011;6:23.*
2. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow
biopsy procedures produce larger core specimens, with less pain, in
less time than with standard manual devices. Hematology Reports
2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free
article] [PubMed] verified March 2015.
3. Swords RT, Anguita J, Higgins RA, et al. A prospective
randomized study of a rotary powered device (OnControl) for bone
marrow aspiration and biopsy. J Clin Pathol 2011; 64(9):809-13.
doi:10.1136/jclinpath-2011-200047.*
4. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a
battery-powered drill system: preliminary results. AJR Am J
Roentgenol 2013;201(5):1093-5. doi:10.2214/AJR.12.10521. Available
at: [PubMed] verified March 2015.
5. Symington K, et al. CT-guided biopsy produces high quality
specimens for diagnosis: a retrospective analysis of 64 consecutive
cases using a powered biopsy device at a community based hospital.
Blood 2013; 122:5381.
6. Clark T, et al. Computational Flow Dynamics and Preclinical
Assessment of a Novel Hemodialysis Catheter. Seminars in Dialysis
2012;25(5):574-581. doi: 10.1111/j.1525-139X.2012.01052.*
7. Data on file at Teleflex. Compared to other competitive
symmetrical tip catheters.
8.
http://www2.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide7.htm
9. Clark TWI, Isu G, Gallo D, Verdonck P, Morbiducci U.
Comparison of symmetric hemodialysis catheters using computational
fluid dynamics. Journal of Vascular and Interventional Radiology.
2015;26(2):252-259. doi: 10.1016/j.jvir.2014.11.004
* Research sponsored by Teleflex Incorporated.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005098/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836orMartina Teichmann-ZindlerSenior
Director Marketing Communications International+49
(0)7151-406-538martina.teichmann@teleflex.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024